Basic information of drug: DB04841
| Drug id | DB04841 |
| Drug name | Flunarizine |
| Description | Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. |
| State | solid |
| Cas number | 52468-60-7 |
| Synonyms | 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine Flunarizina Flunarizine Flunarizinum |
| Sequences | None |
| Indication | Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. |
| Pharmacodynamics | Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. |
| Mechanism of action | Flunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increas... |
| Metabolism | Hepatic, to two metabolites via N-dealylation and hydroxylation. |
| Toxicity | -Flunarizine should be used with care in patients with depression or those being prescribed other agents, such as phenothiazines, concurrently, which may cause extrapyramidal side-effects.
-Acute overdosage has been reported and the observed symptoms were sedation, agitation and tachycardia.
-Treatm... |